I started the day off attending an ISS ( Industry Sponsored Symposium) which reviewed the use of ADC's ( antibody drug conjugates ) in gynecologic cancers. The session included patient case reviews where the audience and speakers were asked what treatment they would choose for a patient with a specific treatment experience and co-morbidities. It was very interesting to "listen in" on the discussion.
The next session was a review by the editors of Gynecologic Oncology and Gyn Oncology Reports of their magazines in terms of readership, reviews and future expansion of clinical guidelines.
The Presidential Invited Speaker was Erin Diehl who presented on "F" Words at Work. With a bit of improv she talked about failure, #failfluence and the importance of reframing the failure to improve ourselves.
Focused Plenary IV on ctDNA was an interesting group of abstracts all dealing with using circulating DNA for prediction of disease.
The Prognostic Value of Circulating Minimal Residual Disease in First-Line Treatment of Ovarian Cancer Dr Shu , Retrospective study , 31 patients tumor tissue and blood tested. There was an association of minimal residual disease (MRD) with plasma sample #gyncsm #SGOmtg pic.twitter.com/a3FB1lkyMT
— Dee Sparacio (@womenofteal) March 17, 2024
Circulating Tumor-Specific HPV DNA is a Sensitive and Specific Biomarker for the Surveillance of Invasive Cervical Carcinoma, Dr Pereira
— Dee Sparacio (@womenofteal) March 17, 2024
ctHPV DNA in this study was sensitive and specific and correlated to patient recurrence
#SGOmtg #gyncsm pic.twitter.com/1bilJpTR8e
Great proof of concept- Circulating #HPV 16/18 DNA detectable with 100% sensitivity in higher stage and 50% in low stage cervical cancer is then detectable at time of recurrence. As it gets validated for practice how often/which subpops will we screen?#SGOMtg #gyncsm pic.twitter.com/2ISFAoHb9g
— Dr.Monica Avila (@MAvilaMD) March 17, 2024
This study included a new term for me - Fragmentomics - the investigation of fragmentation patterns of cell-free DNA (cfDNA).
Early detection of uterine corpus endometrial carcinoma utilizing plasma cfDNA fragmentomics Dr Xu #gyncsm #SGOmtg
— Dee Sparacio (@womenofteal) March 17, 2024
New Classification test for endometrial cancer, sensitive even for early stage , used machine learning model pic.twitter.com/iAshI4vx6D
This was an interesting proof of concept study
Utility of ctDNA as an early predictive biomarker of response to radiation in gynecologic malignancies Dr Wernicke #SGOmtg #gyncsm Natera test, Does ctDNA predict response to RT? Vulvar & cervical cancer , ctDNA identified responders to RT/CRT , Results need to be validated pic.twitter.com/StAE9kbLr7
— Dee Sparacio (@womenofteal) March 17, 2024
Monitoring Minimal Residual Disease Using Circulating Tumor DNA in Patients Treated Long-Term with PARP Inhibitors HGSOC Dr Lee #gyncsm #SGOmtg small study 27 patients, all disease free at time of enrollment in trial , MRD( minimal residual disease) pic.twitter.com/M0VotAR2jZ
— Dee Sparacio (@womenofteal) March 17, 2024
Dr Cosgrove @CaseCosgave an excellent distillation of the ctDNA presentations
— Dee Sparacio (@womenofteal) March 17, 2024
Insightful Q & A - just because we have an approved test, do we have the data? What is the cost to patients? #gyncsm #SGOmtg pic.twitter.com/MeBXGHHwRw
I also attended the Late Breaking Abstract Session.
This was an interesting study of using Avutometinib plus defactinib ( Kinase inhibitors) for Low Grade Serous Ovarian Cancer.
▪︎Avutometinib/ defactinib maintains exceptionally high tumor response rates in heavily pretreated patients with recurrent LGSOC, similar TRAE incidence in 1-3 or ≥4 prior LOT.
— CrozrX (@CrozrX) March 18, 2024
▪︎KRAS mutation not necessary for response (m/wt)
▪︎Consider moving this trial to the frontline pic.twitter.com/icnfvrN61K
Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer:subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Dr Banerjee #gyncsm #SGOmtg High response seen even in these heavily pre treated patients. pic.twitter.com/a8WiKZ36bm
— Dee Sparacio (@womenofteal) March 17, 2024
This study did not reach the endpoint expected so the study was ended. We may want all the studies to be successful but we can always learn from studies that are not working.
UPLIFT (ENGOT-ov67/GOG-3048): Phase 2 trial of Upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-Directed Dolaflexin Antibody-Drug Conjugate (ADC) in PROC Dr Richardson #SGOmtg #gyncsm HGSOC 268 patients, 141 were NApi2-B + ,
— Dee Sparacio (@womenofteal) March 17, 2024
Failed to meet endpoint , Sponsor ended study. pic.twitter.com/OuXgOzCtsV
Focusing on ARID1A in ovarian clear cell and endometriod endometrial cancers.
Clinical activity of tazemetostat, EZH2 inhibitor, among patients w adv endometrioid endometrial cancer and ovarian clear cell carcinoma w & w/out ARID1A mutations (NRG-GY014 Dr Schram #gyncsm #SGOmtg Oral drug, ORR ,PFS OS
— Dee Sparacio (@womenofteal) March 17, 2024
*Tazemetostat did not show activity* pic.twitter.com/4VFHIX957e
This study compared different diagnostic tests for ovarian cancer in post-menopausal women.
OC Test:A multicentre, prospective cohort study investigating diagnostic accuracy among post menopausal women w/ symptoms of suspected OC (the ROCkeTS study): Dr Sundar #gyncsm #SGOmtg Valuing sensitivity over specificity - IOTA ADNEX at 10% would be best in practice pic.twitter.com/kgq8C6FNnZ
— Dee Sparacio (@womenofteal) March 18, 2024
Dr Kathleen Moore distilling Late Breaking abstracts #gyncsm #SGOMtg
— Dee Sparacio (@womenofteal) March 17, 2024
Should we look to use these front line based on biomarkers?
Clear cell -we need to study those who do respond.
How do we drive progress with ADCs? pic.twitter.com/WS1Pvz9OJ3
I was pleased to see the rarer ovarian cancers being discussed.
Thanks to Dr.Monica Avila (@MAvilaMD) and CrozrX (@CrozrX) for sharing their insights into the studies presented.
Next post will be what I learned on Monday the last day of the meeting.
Dee
Every Day is a Blessing!
